These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing. de Vries JF; von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Willemze R; Falkenburg JH; Barge RM Haematologica; 2007 Dec; 92(12):1671-8. PubMed ID: 18055991 [TBL] [Abstract][Full Text] [Related]
7. Percentage of CD34 cells in a minimum 500-cell count in bone marrow trephines of patients with chronic myeloid leukaemia provides the best correlation with aspirate blast count. Elliot V; Marin D; Horncastle D; Elderfield K; Apperley JF; Lampert IA; Naresh K Br J Haematol; 2005 Aug; 130(3):460-1. PubMed ID: 16042700 [No Abstract] [Full Text] [Related]
8. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729 [TBL] [Abstract][Full Text] [Related]
9. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610 [TBL] [Abstract][Full Text] [Related]
10. A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. Moore H; Li NK J Theor Biol; 2004 Apr; 227(4):513-23. PubMed ID: 15038986 [TBL] [Abstract][Full Text] [Related]
11. T cell receptor Vbeta repertoire usage and clonal expansion of T cells in chronic myelogenous leukemia. Li YQ; Yang LJ; Chen SH; Zhang YP; Zhang XL; Luo GX Chin Med J (Engl); 2004 Jun; 117(6):840-3. PubMed ID: 15198883 [TBL] [Abstract][Full Text] [Related]
12. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Greiner J; Schmitt M Eur J Haematol; 2008 Jun; 80(6):461-8. PubMed ID: 18284627 [TBL] [Abstract][Full Text] [Related]
13. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011 [TBL] [Abstract][Full Text] [Related]
14. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Nanda S; Moore H; Lenhart S Math Biosci; 2007 Nov; 210(1):143-56. PubMed ID: 17599363 [TBL] [Abstract][Full Text] [Related]
15. Post-transplantation dynamics of the immune response to chronic myelogenous leukemia. DeConde R; Kim PS; Levy D; Lee PP J Theor Biol; 2005 Sep; 236(1):39-59. PubMed ID: 15967182 [TBL] [Abstract][Full Text] [Related]
16. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567 [TBL] [Abstract][Full Text] [Related]
17. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631 [TBL] [Abstract][Full Text] [Related]
18. [Peripheral blood naive T cell level and its T cell receptor Vbeta repertoire usage profile in patients with chronic myelogenous leukemia]. Geng SX; Li YQ; Chen SH; Yang LJ; Yin QS; Wu XL; Zhang XL Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):413-6. PubMed ID: 16251024 [TBL] [Abstract][Full Text] [Related]
19. [New approach in the diagnosis and monitoring of treatment in chronic myelogenous leukemia]. Matolcsy A Orv Hetil; 2004 Dec; 145(52):2603-9. PubMed ID: 15724695 [TBL] [Abstract][Full Text] [Related]
20. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation. Chen J; Schmitt A; Bunjes D; Chen B; Schmitt M Int J Oncol; 2007 May; 30(5):1119-27. PubMed ID: 17390013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]